A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? Authors: Gianluigi Ferretti, Serena Di Cosimo, Diana Giannarelli, Paolo Carlini, Paola Papaldo, Andrea ...

The Human Epidermal Growth Factor Receptor 2 (HER2) is one of the aggressive subtypes of breast cancer. The HER2 status decides the requirement of breast cancer patients to receive HER2-targeted ...

For Your Patients: What to Know About Breast Cancer HER2 Status — The presence or absence of a specific protein helps guide treatment decisions ...

Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

Breast cancer is the most common malignancy in women, with approximately 20–30% of all diagnosed cases characterized by HER2 overexpression. Several HER2-targeted cytotoxic conjugates have been ...